Associate Professor Richard Haynes
|Tel||+44 (0)1865 743607|
- 3C: A CAMPATH, Calcineurin inhibitor reduction and Chronic allograft nephropathy trial Research Group
- ASCEND: A Study of Cardiovascular Events iN Diabetes Research Group
- BEST-D: Biochemical Efficacy and Safety Trial of Vitamin D Research Group
- SEARCH: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine Research Group
- Trials Methodology Research Group
- UK HARP III Research Group
- MRC Project Leader Track
- MSc in Global Health Science module 8 lead: Clinical Trials and Meta-Analysis
Richard Haynes did his pre-clinical medical studies in Cambridge before moving to Oxford for his clinical studies and qualified in 2000. He came to CTSU for a period of “out of programme” research in 2006 to work on the HPS2-THRIVE trial with Prof Jane Armitage. He completed his training in renal medicine in 2011 and was appointed as an honorary consultant at the Oxford Kidney Unit. Shortly after that he was appointed to the MRC Programme Leader track and he now works on randomized trials and epidemiology (particularly in renal medicine and cardiovascular disease) at CTSU.
Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP).
Staplin N. et al, (2016), Am J Kidney Dis, 68, 371 - 380
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
Herrington W. et al, (2016), The Lancet Diabetes and Endocrinology
The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis.
Quach K. et al, (2016), Am J Kidney Dis
Niacin: old habits die hard.
Haynes R. and Rahimi K., (2016), Heart, 102, 170 - 171
Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD.
Morton RL. et al, (2016), Am J Kidney Dis, 67, 31 - 39